Key facts
- This page summarizes Dan S. Suesskind's Form 3 filing for Nano-X Imaging Ltd. (NNOX).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 30 Apr 2026, 14:31.
Dan S. Suesskind - 18 Mar 2026 Form 3 Insider Report for Nano-X Imaging Ltd. (NNOX)
- Reporting relationship
- Director
- Issuer ticker
- NNOX
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Marina Gofman Feler, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Dan S. Suesskind filed Form 3 for Nano-X Imaging Ltd. (NNOX) on 30 Apr 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001303873
Primary reporting owner
Suesskind Dan S
- Relationship
- Director
- Address
- C/O NANO-X IMAGING LTD., OFER TECH PARK, 94 SHLOMO SHMELTZER ROAD, PETACH TIKVA, ISRAEL
- Signature
- /s/ Marina Gofman Feler, attorney-in-fact
- Signature date
- 30 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NNOX
holding
Ordinary shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,792
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
NNOX
holding
Ordinary shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 17,544
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NNOX
holding
Derivative
Stock Option (right to buy ordinary shares)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary shares
- Underlying amount
- 12,505
- Exercise price
- $64.61
- Footnotes
- F3
NNOX
holding
Derivative
Stock Option (right to buy ordinary shares)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary shares
- Underlying amount
- 50,000
- Exercise price
- $17.63
- Footnotes
- F4
NNOX
holding
Derivative
Stock Option (right to buy ordinary shares)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary shares
- Underlying amount
- 10,000
- Exercise price
- $11.52
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on December 10, 2024 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2027) all underlying shares will be issued to the Reporting Person.
Footnote F2
The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on December 10, 2025 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2028) all underlying shares will be issued to the Reporting Person.
Footnote F3
The options reported in this row were granted to the Reporting Person by the Issuer on February 9, 2021 and are fully vested and exercisable as of the date of this report.
Footnote F4
The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., May 16, 2022), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (May 16, 2026).
Footnote F5
The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (August 14, 2027).
SEC remarks
Exhibit 24.1 Power of Attorney